- Conditions
- Short Stature Children Born Small for Gestational Age (SGA)
- Interventions
- Somapacitan, Norditropin®
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more
Location Directory
Clinical trials in Minneapolis, Minnesota
This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7876
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 757–768 of 7,876 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Lymphatic Diseases, Hematopoietic Malignancy
- Interventions
- Umbilical Cord Blood (UCB)
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Spinal Deformity
- Interventions
- Document intraoperative Maneuvers
- Procedure
- Lead sponsor
- AO Foundation, AO Spine
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- San Francisco, California • Minneapolis, Minnesota • New York, New York + 2 more
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Atlanta, Georgia + 9 more
- Conditions
- Cancer
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Newark, Delaware • Danville, Illinois • Effingham, Illinois + 26 more
- Conditions
- Brain and Central Nervous System Tumors, Neurotoxicity
- Interventions
- temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
- Conditions
- Heart Failure
- Interventions
- CDR132L, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- MTX-474, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
- Conditions
- Clostridioides Difficile Infection
- Interventions
- LMN-201, Placebo
- Drug
- Lead sponsor
- Lumen Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 15
- States / cities
- Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Optune®
- Device
- Lead sponsor
- NovoCure Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,087 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2034
- U.S. locations
- 909
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more